Aplicación de las Nuevas Tecnologías GPS-GPRS para el estudio del comportamiento y mejora de la producción de la raza de lidia

La dehesa es un ecosistema agroforestal único que aúna un óptimo rendimiento económico con una menor incidencia en el medio. En la Península Ibérica hay unas 500.000 hectáreas de dehesas concentradas en Andalucía, Castilla y León, Extremadura, Castilla La Mancha y Madrid. La raza de Lidia es, dentro de las razas autóctonas, por su rusticidad y adaptación, una de las que mejor aprovechan y conservan la dehesa. Las condiciones de cría en grandes fincas (400-500 hectáreas de media), el espacio por cabeza (entre una y seis hectáreas por animal), la movilidad que le da su menor tamaño con respecto a otras razas y su crecimiento en libertad con mínima presencia humana la ha hecho indispensables para el mantenimiento del ecosistema de la dehesa. Con este trabajo pretendemos aplicar una tecnología innovadora como es el GPS-GPRS a la monitorización de la etología del ganado de la raza de Lidia durante todos los periodos de su vida y especialmente en aquellos momentos en los que el animal se ve sometido a diferentes prácticas de manejo. Para ello, se implementará la tecnología de GPS que permite el posicionamiento relativo de un objetivo mediante la captación de la señal de diferentes satélites específicos, lo que proporcionará información precisa sobre: el desplazamiento del ganado en un periodo determinado, las distancias recorridas, el territorio pastoreado, las áreas más querenciosas, su ritmo circadiano, las pautas de comportamiento, etc. Así mismo, el dispositivo incorporará sensores de parámetros biológicos como la temperatura ó el ritmo cardíaco, etc. La implementación de este sistema permitirá, a través del posicionamiento, realizar la óptima gestión de los recursos pastables de la dehesa, permitiendo ahorrar costes en alimentación, infraestructuras y personal, y ofrecer, en un futuro cercano, una atractiva herramienta al ganadero para realizar el control remoto de sus reses

Diet quality index as a predictor of treatment efficacy in overweight and obese adolescents: The EVASYON study

Background & aim: A diet quality index (DQI) is a tool that provides an overall score of an individual''s dietary intake when assessing compliance with food-based dietary guidelines. A number of DQIs have emerged, albeit their associations with health-related outcomes are debated. The aim of the present study was to assess whether adherence to dietary intervention, and the overall quality of the diet, can predict body composition changes. Methods: To this purpose, overweight/obese adolescents (n = 117, aged: 13–16 years; 51 males, 66 females) were recruited into a multi-component (diet, physical activity and psychological support) family-based group treatment programme. We measured the adolescents’ compliance and body composition at baseline and after 2 months (intensive phase) and 13 months (extensive phase) of follow-up. Also, at baseline, after 6 months, and at the end of follow-up we calculated the DQI. Results: Global compliance with the dietary intervention was 37.4% during the intensive phase, and 14.3% during the extensive phase. Physical activity compliance was 94.1% at 2-months and 34.7% at 13months and psychological support compliance were growing over the intervention period (10.3% intensive phase and 45.3% during extensive phase). Adolescents complying with the meal frequency criteria at the end of the extensive phase had greater reductions in FMI z-scores than those did not complying (Cohen''s d = 0.53). A statistically significant association was observed with the diet quality index. DQI-A variation explained 98.1% of BMI z-score changes and 95.1% of FMI changes. Conclusions: We conclude that assessment of changes in diet quality could be a useful tool in predicting body composition changes in obese adolescents involved in a diet and physical activity intervention programme backed-up by psychological and family support

New insights into the genetic etiology of Alzheimer's disease and related dementias

Characterization of the genetic landscape of Alzheimer's disease (AD) and related dementias (ADD) provides a unique opportunity for a better understanding of the associated pathophysiological processes. We performed a two-stage genome-wide association study totaling 111,326 clinically diagnosed/'proxy' AD cases and 677,663 controls. We found 75 risk loci, of which 42 were new at the time of analysis. Pathway enrichment analyses confirmed the involvement of amyloid/tau pathways and highlighted microglia implication. Gene prioritization in the new loci identified 31 genes that were suggestive of new genetically associated processes, including the tumor necrosis factor alpha pathway through the linear ubiquitin chain assembly complex. We also built a new genetic risk score associated with the risk of future AD/dementia or progression from mild cognitive impairment to AD/dementia. The improvement in prediction led to a 1.6- to 1.9-fold increase in AD risk from the lowest to the highest decile, in addition to effects of age and the APOE ε4 allele

Evaluación del acceso a antivirales para el tratamiento de la hepatitis C en un país con recursos limitados

Resumen: Objetivos: Estimar la proporción de pacientes que acceden al tratamiento de la hepatitis C con antivirales de acción directa (AAD) en Argentina, y evaluar factores asociados a la falta de acceso. Métodos: Estudio de cohorte transversal que incluyó la totalidad de prescripciones consecutivas de AAD realizadas entre enero de 2016 y febrero de 2017 por centros de salud que participan en el proyecto de telemedicina ECHOTM dirigido por el Hospital Italiano de Buenos Aires. Resultados: Se incluyeron 143 prescripciones de tratamiento. El acceso global fue del 70% (IC 95%: 62-77%). Pertenecer al sistema de salud público fue el único factor independiente asociado con la falta de acceso al tratamiento [OR 4.98 (IC95% 2.05-12.09)]. Conclusión: Los pacientes con hepatitis C pertenecientes al sistema de salud público tienen 4 veces más chances de no acceder a tratamiento con AAD que los pacientes con dependencia de otros sistemas de salud (medicina privada u obras sociales). Abstract: Aims: To estimate the number of patients that have access to treatment of hepatitis C with direct-acting antivirals in Argentina and evaluate the factors associated with the lack of access. Materials and methods: A cross-sectional cohort study was conducted that included all the consecutive prescriptions of direct-acting antivirals issued at health centers that participated in the ECHOTM telemedicine project directed by the Hospital Italiano de Buenos Aires, within the time frame of January 2016 and February 2017. Results: A total of 143 treatment prescriptions were included and overall access was 70% (95% CI 62-77%). The only independent factor associated with a lack of treatment access was coverage by a public healthcare system (OR 4.98 [95% CI 2.05- 12.09]). Conclusion: Patients with hepatitis C that were covered by a public healthcare system had a 4 times higher chance of not having access to treatment with direct-acting antivirals than patients covered by other healthcare systems (private insurance or the social welfare system). Palabras clave: Antivirales de acción directa, Acceso, Hepatitis C, Sistemas de salud, Barreras, Keywords: Direct-acting antiviral agents, Access, Hepatitis C, Healthcare systems, Barrier

Access to direct-acting antivirals for the treatment of hepatitis C in a country with limited resources

Aims: To estimate the number of patients that have access to treatment of hepatitis C with direct-acting antivirals in Argentina and evaluate the factors associated with the lack of access. Materials and methods: A cross-sectional cohort study was conducted that included all the consecutive prescriptions of direct-acting antivirals issued at health centers that participated in the ECHOTM telemedicine project directed by the Hospital Italiano de Buenos Aires, within the time frame of January 2016 and February 2017. Results: A total of 143 treatment prescriptions were included and overall access was 70% (95% CI 62-77%). The only independent factor associated with a lack of treatment access was coverage by a public healthcare system (OR 4.98 [95% CI 2.05- 12.09]). Conclusions: Patients with hepatitis C that were covered by a public healthcare system had a 4 times higher chance of not having access to treatment with direct-acting antivirals than patients covered by other healthcare systems (private insurance or the social welfare system). Resumen: Objetivos: Estimar la proporción de pacientes que acceden al tratamiento de la hepatitis C con antivirales de acción directa (AAD) en Argentina, y evaluar factores asociados a la falta de acceso. Métodos: Estudio de cohorte transversal que incluyó la totalidad de prescripciones consecutivas de AAD realizadas entre enero de 2016 y febrero de 2017 por centros de salud que participan en el proyecto de telemedicina ECHOTM dirigido por el Hospital Italiano de Buenos Aires. Resultados: Se incluyeron 143 prescripciones de tratamiento. El acceso global fue del 70% (IC95%: 62-77%). Pertenecer al sistema de salud público fue el único factor independiente asociado con la falta de acceso al tratamiento [OR 4.98 (IC95% 2.05-12.09)]. Conclusión: Los pacientes con hepatitis C pertenecientes al sistema de salud público tienen 4 veces más chances de no acceder a tratamiento con AAD que los pacientes con dependencia de otros sistemas de salud (medicina privada u obras sociales). Keywords: Direct-acting antivirals, Access, Hepatitis C, Healthcare systems, Barriers, Palabras clave: Antivirales de acción directa, Acceso, Hepatitis C, Sistemas de salud, Barrera

Implantation of a heterologous dermo-epidermal skin substitute in a patient with deep dermal burn that enhances biomechanical and functional recovery: Case report

In Mexico, burns are considered a public health problem; approximately 93% of all burned patients are treated at public hospitals. For patients undergoing extensive burns, prompt skin coverage avoids potential complications, is life-saving, and is the key for acceptable functional and aesthetic results. Many efforts have been undertaken to find new strategies for the treatment of burns. The aim of this study was to create a human Dermo-Epidermal Skin Substitute (hDE-SS) by combining heterologous keratinocytes and fibroblasts cultured onto Radio-sterilized Human Amnion (RHA), suitable for the treatment of patients with deep dermal burns. The manufacture of hDE-SS was carried out under sterile conditions in a Class 100 Cleanroom located inside the Laboratory of Biotechnology at the National Center of Research and Attention for Burn Patients (CENIAQ, its acronym in spanish). The heterologous cells were obtained from skin remnants collected from elective aesthetic surgeries. RHA used as a scaffold was obtained from placental tissue irradiated with 25 kGy of gamma radiation. Viable constructs were obtained, revealing a positive immunophenotype for fibroblast surface antigen (1B10) and negative for human alpha smooth muscle actin protein (α-sma). Keratinocytes were positive for CK5 and CK10 to a lesser extent. hDE-SS was implanted in one patient with a deep dermal burn who fulfilled the inclusion criteria for this study. The implanted patient was followed up through days 7, 14, 21, 35, and 92 post-implantation using photographic monitoring and measurement of the following: viscoelasticity (R6); net elasticity (R5); maximal extension (R0), and hydration, melanin, and erythema with a Cutometer®. The employment of hDE-SS in a deep dermal burn showed clinical re-epithelization within a 7-day period favored by cellular migration, due to the presence of fibroblasts and keratinocytes. Also, the functional and mechanical quality of the skin was measured with the Cutometer®, demonstrating that it is optimal and similar to controls of healthy skin and an autograft, justifying the usage of hDE-SS. Keywords: Heterologous keratinocytes, Heterologous fibroblasts, Human dermo-epidermal skin substitute, Human amnion, Deep dermal burn, Suction method, Biomechanics, Cutomete